- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic migraine
- Meeting Date: March 2020
- Public Summary Document (PSD) March 2020 PBAC Meeting - (PDF 831KB)
- Public Summary Document (PSD) March 2020 PBAC Meeting - (Word 167KB)
Fremanezumab – March 2020
Fremanezumab: Injection 225 mg in 1.5 mL pre-filled syringe; Ajovy®
Last updated
3 July 2020